A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Jan 2019
At a glance
- Drugs Mirikizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms OASIS-1
- Sponsors Eli Lilly
- 17 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated
- 17 May 2018 Planned End Date changed from 19 Dec 2019 to 19 Mar 2020.